Here's what to expect this week on Diagnostic Imaging.
In this week’s preview, here are some highlights of what you can expect to see coming soon:
When it comes to COVID-19 detection, time is critical. This week, Diagnostic Imaging speaks with the leadership of RADLogics about their current artificial intelligence (AI) system that is designed to streamline workflow. CEO Moshe Becker shares not only the benefits of the system for radiologists, but also the impact on patient care. In addition, he also addresses what makes this AI system different from others in light of a new study that calls the efficacy and accuracy of COVID-19-related machine learning into questions. Look for the interview later this week.
For more COVID-19 AI coverage, click here.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Recent research has shed a great deal of light on the role of the blood-brain barrier in brain aging diseases. This week, new investigative findings will be published about the impact of having a faulty blood brain barrier and how it might affect the brain. Look for details later this week.
For more coverage of the blood brain barrier, click here.
While tuberculosis is rare in the United States, that isn’t necessarily the case around the world. And, individuals who have active infections pose a dangerous risk to those around them. In a study to-be-published later this week, investigators take a deeper look at how the use of chest X-ray or chest CT allow for more timely screenings and diagnosis. Look for the story later this week.
For additional tuberculosis coverage, click here.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.